Neos Therapeutics shares down, despite FDA approval of ADHD drug

19 September 2017

US modified-release drug delivery technologies specialist Neos Therapeutics has received approval from the US Food and Drug Administration for Adzenys ER (amphetamine) extended-release oral suspension, with the news sending the firm’s share more than 5% lower in after-hours trading.

Adzenys ER will be commercially available in early 2018, the company noted.

Texas-based Neos Therapeutics says it is the only company to offer both branded amphetamine and methylphenidate products in extended-release dosage forms. Once commercially available, Adzenys ER oral suspension will be the third Neos extended release product for the treatment of attention deficit hyperactivity disorder (ADHD). The other Neos extended-release products for the treatment of ADHD are Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, a bioequivalent to Adderall XR (mixed amphetamine salts), which is marketed by Ireland-based pharma company Shire (LSE: SHP), and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK